Who we are

Recognized leaders in cross border and local markets

Management Team

Bing Li

Bing Li, Ph.D.

CEO

Debra Yu

Debra Yu, MD

President & CBO

Jing Ji

Jing Ji, MD

SVP, Medical and Clinical Development

Nathan Chen

Nathan Chen

VP, Regulatory Affairs

David Li

David Li, Ph.D.

Head of CMC and Supply Chain

Brianne Jahn

Brianne Jahn

Head of Operations & Finance, US

Jennifer Huang

Jennifer Huang

VP, Legal & Compliance

Tao Ji

Tao Ji

VP, China Finance

Additional Team Members

Board of Directors

Bing Li

Bing Li, Ph.D.

CEO

Konstantin Poukalov

Konstantin Poukalov

Executive Chairman

Adam Stone

Adam Stone

Neil Kumar

Neil Kumar, Ph.D.

Tassos Gianakakos

Tassos Gianakakos

Our Investors

Perceptive Advisors

Founded in 1999, Perceptive Advisors is a leading life sciences focused investment firm with over $7 billion of regulatory assets under management as of June 30, 2020. Since inception, Perceptive Advisors has focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare.

Perceptive Advisors’ investment activity is focused on identifying both private and public companies in the life sciences and medical technology sectors and currently has investments in over 150 companies. The team at Perceptive Advisors consists of trained scientists, physicians, and financial analysts who are passionately committed to identifying innovation that can drive critical change to current treatment paradigms. Perceptive Advisors invests across the capital structure and throughout a company’s growth cycle, which provides access to a broad universe of management teams and companies seeking flexible capital solutions. Perceptive Advisors is also an active investor in pre-IPO financing rounds known as “crossovers.” Perceptive Advisors has invested in over 80 private companies since 2013 and in 2019 met with over 200 private companies in the evaluation of private growth financing rounds, crossovers, and pre-IPO analysis.

See website

Program Partners

BridgeBio Pharma

BridgeBio’s mission is to find, develop, and deliver breakthrough medicines for genetic diseases to patients as quickly and safely as possible. The company creates a bridge from remarkable advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible.

Read More

Myokardia

MyoKardia is pioneering a precision medicine approach to discover, develop, and commercialize targeted therapies for the treatment of serious cardiovascular diseases. MyoKardia’s scientists have discovered a portfolio of small molecule therapeutics aimed at the muscle proteins of the heart and intended to correct the excessive contraction, impaired relaxation, or insufficient contraction underlying diseases of systolic and diastolic dysfunction.

Read More

Navire Pharma

Navire, an affiliate of BridgeBio Pharma, is harnessing advances in the understanding of the role of SHP2 (Src homology region 2-containing protein tyrosine phosphatase) in cancer signaling to develop novel therapies for rare and difficult-to-treat cancers. The company develops small molecules inhibitors to SHP2, a phosphatase that mediates signaling of multiple pathways harnessed by tumors, thereby decreasing tumor growth while also enhancing patients’ immune response.

Read More

QED Therapeutics

QED, an affiliate of BridgeBio Pharma, focuses on precision medicine for FGFR-driven cancers and diseases. QED, derived from the Latin “Quod Erat Demonstrandum” means “Thus, It Has Been Proven.” The company is focused on the development of infigratinib, a selective FGFR1-3 inhibitor.

Read More